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                                  ABSTRACT 
  Introduction      Given the safety issues of non-
steroidal anti-inﬂ  ammatory drugs (NSAID) and the 
robustness of guidelines, making treatment choices 
in daily clinical practice is increasingly difﬁ  cult. This 
study aimed systematically to analyse the opinions 
of a multidisciplinary European expert panel on the 
appropriateness of different NSAID, with or without the 
use of a proton pump inhibitor (PPI), in individual patients 
with chronic rheumatic disease.   
  Methods      Using the Research and Development/
University of California at Los Angeles appropriateness 
method, the appropriateness of ﬁ  ve (non-)selective 
NSAID with or without a PPI was assessed for 144 
hypothetical patient proﬁ  les, ie, unique combinations 
of cardiovascular and gastrointestinal risk factors. 
Appropriateness statements were calculated for all 
indications.  
  Results      All options without PPI were considered 
appropriate in patients with no gastrointestinal/
cardiovascular risk factors. Cyclooxygenase-2 selective 
inhibitors (C2SI) alone and non-selective NSAID plus PPI 
were preferred for patients with elevated gastrointestinal 
risk and low cardiovascular risk. Naproxen plus PPI was 
favoured in patients with high cardiovascular risk. For the 
combination of high gastrointestinal/ high cardiovascular 
risk the use of any NSAID was discouraged; if needed, 
naproxen plus PPI or a C2SI plus PPI could be considered.   
  Discussion      The panel results may support treatment 
considerations at the level of individual patients, 
according to their gastrointestinal/cardiovascular risk 
proﬁ   le.      
  Non-steroidal anti-inﬂ   ammatory drugs (NSAID) 
belong to the mainstay treatments for chronic rheu-
matic diseases. Despite similar effectiveness,    1   –    4    
the currently available NSAID show pronounced 
differences in their safety proﬁ  le. Classic NSAID 
carry a substantial risk of upper and lower gastro-
intestinal events, varying from mild symptoms to 
gastroduodenal ulcers and related serious compli-
cations.    5        6    Besides the dosage and frequency of 
NSAID use, several patient conditions have been 
identiﬁ  ed to increase the risk of upper gastroin-
testinal complications, including advanced age, a 
history of gastrointestinal ulcer and concomitant 
treatment with corticosteroids, aspirin or antico-
agulants.    7    The later introduced cyclooxygenase-2 
selective inhibitors (C2SI) exhibit a more favour-
able gastrointestinal safety proﬁ  le,    8    albeit with 
individual differences. However, serious concerns 
about their cardiovascular toxicity have led to the 
market withdrawal of rofecoxib and regulatory 
warnings (European Medicines Agency) for the 
others.    9    Following new reports that the increased 
cardiovascular risk may also apply to non-selective 
NSAID, the US Food and Drug Administration 
issued ‘black box’ safety warnings for the entire 
NSAID drug class.    10    Consequently, the choice 
between the various NSAID is dominated by an 
uneasy application of the ‘least harm principle’, 
balancing the various potential adverse events. 
Despite the available recommendations, there are 
still several ‘historical’ myths that may perpetu-
ate wrong habits and beliefs in clinical practice.    11    
In addition, guidelines are generally insufﬁ  ciently 
detailed to support, at the level of the individual 
patient, a treatment choice that duly takes into 
account (combinations of) different cardiovascu-
lar and gastrointestinal risk factors. To bridge this 
gap between science and practice, we conducted 
a European panel study, combining the evidence 
from clinical studies with the opinions of experts 
from various disciplines. 
  METHODS 
  The Research and Development/University of 
California at Los Angeles (RAND/UCLA) appropri-
ateness method    12   –    14    was used. 
  Panel  composition 
  The panel consisted of 18 experts from 10 European 
countries, representing all relevant disciplines (see 
appendix 1). Selection of experts was based on 
their speciﬁ  c expertise in the ﬁ  eld of NSAID.   
  Panel  process 
  The panel ﬁ  rst met in January 2008 to set up the 
initial rating structure, ie, study population, treat-
ment options (distinctive NSAID or NSAID groups) 
and clinical variables (relevant to the choice of dif-
ferent NSAID), see supplementary table 1, avail-
able online only. 
  Using an electronic rating program, panel-
lists individually assessed the appropriateness 
of selected therapeutic options for a number of 
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  Statistical  analysis 
  A correlation matrix (using Spearman’s correlation coefﬁ  cient 
for ordinal variables) was applied to investigate the agreement 
between individual ratings, within and across the various speci-
alities included.     
  RESULTS 
  Panel  results 
  Of all theoretical indications rated in this study, approximately 
one-third were deemed inappropriate, largely attributable to 
classic NSAID without proton pump inhibitors (PPI) (see sup-
plementary   ﬁ  gure 1  , available online only). The percentage of 
appropriate indications was highest for naproxen plus PPI, fol-
lowed by celecoxib alone and ibuprofen/diclofenac plus PPI. The 
outcomes were uncertain for more than half of the indications, 
of which approximately a quarter was caused by disagreement 
(strong opposite opinions), with highest values for naproxen 
plus PPI and celecoxib with or without PPI. Global ﬁ  gures show 
considerable variations in ratings over and within all specialties 
(supplementary   ﬁ  gure 2  , available online only).     
  For the patient proﬁ  le without any unfavourable conditions, 
all NSAID without PPI (both classic and C2SI) were considered 
appropriate (supplementary   ﬁ  gure 1  , available online only). The 
presence of any gastrointestinal risk factors led to inappropri-
ate outcomes of classic NSAID alone in the majority of cases. 
In patients with a low cardiovascular risk and a history of no 
or uncomplicated upper gastrointestinal events, celecoxib alone 
and classic NSAID plus PPI were generally favoured over the 
other options (  ﬁ  gure 1  ). The combination of low cardiovascular 
risk and a history of complicated upper gastrointestinal events 
lowers the appropriateness of C2SI alone and naproxen plus PPI 
(uncertain). For patients with high cardiovascular risk, naproxen 
plus PPI showed the highest percentage of appropriate indica-
tions (46%) ( ﬁ  gure 1  ), whereas the other options scored between 
mutually exclusive proﬁ  les on a nine-point scale (reference val-
ues: 1, inappropriate; 5, uncertain; 9, appropriate). Following 
the RAND/UCLA deﬁ  nition, a treatment had to be considered 
appropriate if the expected beneﬁ  ts exceeded the potential neg-
ative consequences by a sufﬁ  cient margin.    12    Financial costs or 
other potential constraints had to be disregarded. Together with 
the rating program, the experts received a literature overview 
of which the scope and boundaries were determined during the 
ﬁ  rst meeting. This (electronic) document was rather an exten-
sive data overview than a comprehensive synthesis of clinical 
evidence, and reﬂ  ected the published English-language literature 
from 1998 to 2008, with a focus on reports with the highest 
level of evidence. 
  The results of the ﬁ  rst round were discussed during a plenary 
meeting (June 2008), leading to a revision of the rating struc-
ture and reﬁ  nement of some treatment options and deﬁ  nitions 
(see box 1).   Thereafter a second individual rating round took 
place, including 144 different patient proﬁ  les and 10 treatment 
options. Based on the median score and the extent of agreement 
between the panellists, appropriateness statements (appropri-
ate, inappropriate, uncertain) were calculated for all indications, 
according to common RAND/UCLA rules.    13    Indications were 
deemed appropriate if the median panel score was between 7 
and 9, and inappropriate if the median was between 1 and 3, 
both without disagreement between panellists. Disagreement 
was deﬁ  ned as a situation in which at least six panellists scored 
in each of the sections 1–3 and 7–9. All indications not falling 
in the categories ‘appropriate’ and ‘inappropriate’ were labelled 
‘uncertain’. 
  A third panel meeting (November 2008) was organised to 
discuss the second round results and their applicability in daily 
clinical practice. The ﬁ  nal ratings were embedded in an elec-
tronic tool that allows quick reference of the appropriateness 
statements for any of the patient proﬁ  les included.   
Box 1  Overview of treatment options, variables and deﬁ  nitions used in the second rating round
▶   Patient  population
   ▶  Patients with a chronic rheumatic disease for whom treatment with a NSAID is considered
▶   Treatment  options
   ▶    Ibuprofen, diclofenac, naproxen, celecoxib, etoricoxib, all without or with the addition of a PPI
▶  Clinical variables used for the construction of patient proﬁ  les
   ▶  Age (<65 years; ≥65 years)
   ▶  History of upper gastrointestinal events (none; uncomplicated; complicated)
   ▶    Uncomplicated: previous uncomplicated oesophageal, gastric or duodenal event (eg, signiﬁ  cant symptoms, ulcer discovered 
by a clinically indicated work-up);
   ▶  Complicated: previous complicated oesophageal, gastric or duodenal event (bleeding, obstruction or perforation)
   ▶  Cardiovascular risk (low; high)
   ▶    10-Year risk of fatal cardiovascular disease (heart attack, stroke), based on the (country-speciﬁ  c) HeartScore of the 
European Society of Cardiology; low: <10%; high: ≥10%
   ▶  Use of low-dose aspirin (yes/no; only in patients with high cardiovascular risk)*
   ▶  Use of anticoagulants or other antiplatelet agents (yes/no)
   ▶  Anticoagulants: warfarin, acenocoumarol
   ▶  Antiplatelet agents: other than low-dose aspirin, for example clopidogrel (only in patients with high cardiovascular risk)*
   ▶  Use of systemic corticosteroids (yes/no)
   ▶  Treatment pattern (intermittent; continuous)
   ▶  Intermittent: short-term but repetitive
   ▶  Continuous: chronic use with standard doses
*It is assumed that patients with low cardiovascular risk do not take low-dose aspirin or other antiplatelet agents.
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  DISCUSSION 
  This study combines the insights and views from different 
perspectives to determine the appropriateness of different 
NSAID regimens in patients with chronic rheumatic disease. 
So far, two other studies on the same topic that used a simi-
lar approach have been published. However, the ﬁ  rst study 
could be considered outdated because at the time of the study 
(2002),    15    there were just a few indications of the cardiovascu-
lar risk of NSAID, causing the cardiovascular risk to inﬂ  uence 
the ratings minimally. The second, recently published, study by 
Chan   et al      16    had an international multidisciplinary panel that 
rated the appropriateness of six therapeutic regimens (non-
naproxen, naproxen, C2SI; all with and without PPI/misopros-
tol) for 288 clinical vignettes. Similarities in results with our 
study were ﬁ  rst seen for the extremes of the patient population 
(with no cardiovascular and gastrointestinal risk factors at all: 
classic NSAID alone as appropriate; both a high cardiovascu-
lar and gastrointestinal risk: use of any NSAID is discouraged) 
and for those with low/average cardiovascular risk and high 
gastrointestinal risk (classic NSAID plus PPI or C2SI plus PPI). 
Differences were noted for the appropriateness of C2SI alone 
in patients with low cardiovascular risk and low/average gas-
trointestinal risk (being appropriate in our study vs uncertain). 
Divergence may partly be due to differences in methodology 
(eg, distinguishing between different members of the C2SI class 
in our study) and also in timing; our study was conducted 2 
years after that of Chan   et al  ,    16    and in the meantime many new 
study reports became available. Knowledge progression, chang-
ing guidelines and increased expertise may inﬂ  uence treatment 
decisions, which emphasises the need for periodic updates of 
panel results, including ours. 
0% and 12%. Appropriateness ratings for naproxen plus PPI 
showed a negative association with the severity of gastrointes-
tinal risk factors and concomitant use of low-dose aspirin. In 
the highest risk category (high cardiovascular risk, on aspirin, 
history of complicated upper gastrointestinal events), none of 
the options was rated appropriate, whereas 56% of indications 
were deemed inappropriate (  ﬁ  gure 1  ). Uncertain outcomes were 
largely the result of equivocal (ratings in section 4–6) or diffuse 
rating patterns. 
  Additional analyses showed that the agreement between pan-
ellists of the same speciality was not higher than that across spe-
cialities. The panel discussion after the second round revealed 
that much of the disagreement was related to different individ-
ual perceptions of the notion of appropriateness. The deﬁ  nition 
implies that the expected beneﬁ  ts should outweigh the poten-
tial negative consequences by ‘a sufﬁ  cient margin’, but does 
not specify what constitutes ‘sufﬁ  cient’. Particularly for options 
with the addition of a PPI this led to divergent opinions for 
which no consensus could be reached. As ﬁ  nancial costs had to 
be disregarded, some panellists considered a PPI as being always 
appropriate because they assumed that PPI carry a low poten-
tial for clinical harm. Others mentioned that they had rated the 
addition of a PPI only appropriate if they considered it a clear 
gain of gastrointestinal safety, pointing to a different risk avoid-
ance attitude.   
  Electronic  tool 
  Data were embedded in an electronic tool that allows the user to 
select a patient proﬁ  le and to see the panel recommendations for 
that proﬁ  le, including the distribution of panel ratings   (  ﬁ  gure 2  ). 
The program is accessible via http://www.e-hims.com/Sensar.     
•Non-selec ve NSAID3
￿C2SI4
￿Non-selec ve NSAID1 + PPI
￿Ibuprofen/diclofenac + PPI
￿Celecoxib + PPI
￿Naproxen + PPI
￿Naproxen + PPI
￿Avoid any NSAID if possible 
￿If needed:
-  Diclofenac/naproxen + PPI 
-  C2SI4 + PPI
Low
High
Low High GI risk1
CV risk2
1 Increasing GI risk is related to the number of GI risk factors that are present (previous upper
GI event, age ≥ 65 years,  con nuous NSAID use, and concomitant use of aspirin/an -
coagulants/cor costeroids).
2 CV risk: 10-year risk of fatal CV event (low < 10%; high ≥ 10%).
3 Ibuprofen/diclofenac/naproxen
4 Celecoxib, etoricoxib
  Figure  1         Global pattern of appropriate treatments in relation to gastrointestinal (GI) and cardiovascular (CV) risk levels. C2SI, cyclooxygenase-2 
selective inhibitor; NSAID, non-steroidal anti-inﬂ  ammatory drug; PPI, proton pump inhibitor.       
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